Status
Conditions
Treatments
About
In this study, patients with active mild to moderate UC with or without PSC will be randomized to receive either bromlein or placebo along with low FODMAP diet for 8 weeks.
IBDQ, SCCAIQ, CRP, TAC, TNF-a will be measured before and after the intervention.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
84 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Reihaneh Samieeian, MSc; Azita Hekmatdoost, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal